Premium
Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C
Author(s) -
O'Brien C.
Publication year - 2006
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/j.1365-2893.2006.00757.x
Subject(s) - clinical trial , chronic hepatitis , medicine , intensive care medicine , clinical study design , population , hepatitis , intervention (counseling) , alternative medicine , hepatitis c , randomized controlled trial , pathology , environmental health , immunology , psychiatry , virus
Summary. Many of the major advances in treating patients for chronic hepatitis C have been made based on the results of randomized, double‐blind, controlled clinical trials. However, given the large number of hepatitis C medications in development, physicians need to understand the unique elements and types of clinical trials in order to make accurate comparisons of differing drug efficacy claims. Clinicians also need to be aware of the various factors that can influence the outcomes and interpretations of these trials, irrespective of the intervention under study. For example, similar trials conducted in the United States and Europe may have different outcomes simply because the study populations differ. Thus, both trial design and patient population are important considerations in the design and analysis of clinical trials for patients with chronic hepatitis C.